BioInvent Interim Report
1 January – 30 June 2010
July 14, 2010 03:11 AM Eastern Daylight Time
LUND, Sweden--(EON: Enhanced Online News)--
l Phase II data presented in May shows that the antithrombotic effect of TB-402 is better than
enoxaparin, the current standard treatment.
l In May BioInvent and ThromboGenics achieved a milestone corresponding to EUR 10 million when
development partner Roche launched a new clinical study with the product candidate TB-403.
l Reorganisation will give greater focus on the company’s proprietary drug development. Adapted
manufacturing capacity to in house needs, reduces fixed costs by around SEK 15 million on an
l In March BioInvent entered into a partnership with Human Genome Sciences to develop and
commercialise therapeutic antibodies.
l A directed new share issue that raised SEK 150 million for the company before transaction costs
was implemented in February.
l Net revenues for January - June 2010: SEK 63.1 million (47.1).
l Loss after tax for January - June 2010 amounted to SEK -60.7 million (-88.2) and the loss after tax
per share was SEK -1.01 (-1.59).
l Current investments together with cash and bank as of 30 June 2010: SEK 138.7 million, excluding
share of milestone payments for TB-403 received in July, (150.5).
l Cash flow from current operations and investment activities for January – June 2010: SEK -89.7
BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The
Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer and
Comments by the CEO
BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic
surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than
enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company’s partner,
ThromboGenics, will now prioritis